– Biotech with liquidation value nearly 3x above current price.
– A recent spin-off from $BLUE, with BLUE CEO migrating to TSVT.
– Down 63% since the spin-off.
– 2/3rds of market cap in net cash and 50% ownership of ABECMA worth more than $30/share.
– ABECMA is first in class treatment for multiple myeloma marketed in conjunction with $BMY, with demand outstripping supply and heading for $1.4bn peak revenue.
$TSVT valuation: $10.5/share of net cash and 50% ownership of ABECMA worth more than $30/share.
Exp. gain: 2x-3x upside with no long-term downside.
Full TSVT write-up (free guest account required):